Tag: antiplatelet

1. After successful transcatheter aortic valve replacement, compared to an anti-platelet based strategy, patients that received an anti-coagulation strategy including rivaroxaban at a dose of 10 mg daily had a higher risk of death, thromboembolic complications, and bleeding. Evidence Rating: 1 (Excellent) Transcatheter aortic-valve replacement (TAVR) is a treatment option for patients...
Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the GLOBAL LEADERS Randomized Clinical Trial 1. Bleeding after percutaneous coronary intervention (PCI) was more common in women, but the effect of two antiplatelet strategies on death and new Q-wave myocardial infarction following PCI did...
Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial While dual antiplatelet therapy (DAPT) is the standard of care post-percutaneous coronary intervention (PCI) using drug-eluting stents (DES), the optimal duration of...
Patients with a history of occlusive vascular disease who are on antithrombotic therapy are at an increased risk of intracerebral hemorrhage. Generally, antithrombotic therapy is discontinued after intracerebral hemorrhage in these patients. However, no published randomized trials have studied the long-term safety of antithrombotic therapy in survivors of intracerebral...
Treatment and Long-Term Clinical Outcomes of Incidental Pulmonary Embolism in Patients With Cancer: An International Prospective Cohort Study Venous thromboembolism (VTE) is a common complication in patients with cancer. Often, VTEs are incidentally detected on imaging studies undertaken for cancer staging or evaluation of treatment response. Current guidelines recommend that...
1. Standardized score suggests that prolonged dual antiplatelet therapy (DAPT) is harmful for patients with low DAPT scores. 2. Prolonged DAPT may reduce risk of ischemic events in patients with high scores receiving paclitaxel-eluting stents. Evidence Rating Level: 2 (Good) Study Rundown: The DAPT score is a new, standardized system of predicting...
1. A prediction model for assessing the harm and benefit of long-term dual antiplatelet therapy after percutaneous coronary intervention (PCI) was able to accurately identify patients with the highest risk of ischemia. 2. Patients with high-risk of ischemia after PCI who were maintained on aspirin and thienopyridine had a significantly...
1. In patients requiring percutaneous coronary intervention (PCI) and long-term oral anticoagulation, treating with clopidogrel alone (i.e., double therapy) significantly reduced the risk of bleeding when compared to a combination of aspirin and clopidogrel (i.e., triple therapy). 2. There were no differences between the two groups in the risk of...
1. From a systematic review, longer duration dual-antiplatelet therapy was associated with a decreased risk of myocardial infarction in patients with drug-eluting stents. 2. However, longer duration therapy also increased the risk of major bleeding and all-cause mortality. Evidence Rating Level: 1 (Excellent) Study Rundown: Patients with coronary artery disease (CAD) who...
1. Extended duration dual antiplatelet therapy was not found to be linked to an increased all-cause, cardiovascular, or non-cardiovascular mortality risk. Evidence Rating Level: 1 (Excellent) Study Rundown: Recent studies have shown conflicting evidence as to the safety of long term dual antiplatelet therapy for patients at risk of...